(Health-NewsWire.Net, July 23, 2018 ) Cell-free DNA (cfDNA) are non-encapsulated fragments of DNA molecule present in blood and urine that has huge screening and diagnostic applications. CfDNA is used for fetal DNA screening tests to detect chromosomal abnormalities, as a biomarker for specific mutations detection in cancer patients, as a biomarker to detect post transplantation rejection, and other applications. According to the Center of Disease Control and Prevention, around 6,000 babies are born with Down syndrome every year that is nearly 1 in every 700 babies and the disease incidence is increased by about 30% between 1979 and 2003. Further, according to the study by World Health Organization, approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades.
Top Manufacturer Detail-
Natera, Inc., Beijing Genomics Institute, F. Hoffmann-La Roche (Roche), Laboratory Corporation of America Holdings, Illumina, Inc., Guardant Health, Trovagene, Inc., Biocept, Inc
FREE | Request Sample Copy is Available: http://www.reportsweb.com/inquiry&RW00011868224/sample
The "Global Cell-free DNA Testing Market" is estimated to witness a CAGR of 26.5% during the forecast period 2017-2023. The market is analyzed based on three segments, namely test types, application, and regions.
The cfDNA testing market is booming due to advanced maternal age, increasing number of chronic diseases, change in lifestyle that leads to lifestyle diseases like cancer, and unhealthy food habits. The rising disease incidence along with the increasing medical spending and healthcare expenditure provide opportunities for molecular diagnostics company to come up with more number of innovative tests in the market. However, there is a huge market space for molecular diagnostic companies to come up with novel tests directing on transplantation rejection cases like liver, lung, etc, in the near future.
Browse Complete Report: http://www.reportsweb.com/cell-free-dna-testing-market-global-drivers-restraints-opportunities-trends-and-forecasts-2017-2023
Table of Contents
1 INDUSTRY OUTLOOK 9
1.1 Industry overview 9
1.2 Total addressable market 9
1.3 Industry Trends 10
2 Report Outline 11
2.1 Report Scope 11
2.2 Report Summary 11
2.3 Research Methodology 12
2.4 Report Assumptions 12
3 Market Snapshot 13
3.1 Market Definition-Infoholic Research 13
3.2 Importance of Cell-Free DNA testing 13
3.3 Complications of Cell-Free DNA testing 13
3.4 Segmented Addressable Market (SAM) 14
3.5 Industry Trends 14
3.6 Related Markets 16
3.6.1 Liquid biopsy market 16
3.6.2 Transplantation Diagnostics Market 16
4 Market Outlook 16
4.1 Overview 16
4.2 Regulatory framework 17
4.3 Funding scenario 18
4.4 Market segmentation 19
4.5 PEST Analysis 20
4.6 Porter 5(Five) Forces 21
5 Market Characteristics 22
5.1 DRO-Global Cell-free DNA testing Market Dynamics 22
5.1.1 Drivers 22
5.1.1.1 Rising incidence of babies with chromosomal disorders due to increasing number of late pregnancies 22
5.1.1.2 Rising number of cancers 23
5.1.1.3 Growing demand through non-invasive procedures for early disease diagnosis 23
5.1.2 Opportunities 24
5.1.2.1 Increase healthcare spending and growing healthcare awareness in emerging countries 24
5.1.2.2 Increase in mergers & acquisitions 24
5.1.3 Restraints 24
5.1.3.1 High test cost with less reimbursement facilities 24
5.1.3.2 Ethical issues 25
5.1.3.3 Lack of skilled professionals for performing advanced diagnostic testing 25
6 Test Types: Market Size and Analysis 28
6.1 Overview 28
6.2 Non-invasive prenatal testing (NIPT) 29
6.3 Circulating tumour DNA tests 30
6.4 Donor-derived cell free DNA tests 32
7 Application: Market Size and Analysis 33
7.1 Overview 33
7.2 Prenatal testing 35
7.3 Cancer 35
7.4 Transplantation diagnostics 36
Place Direct Purchase order For Complete report: http://www.reportsweb.com/inquiry&RW00011868224/discount
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|